Advertisement

BMC Medical Genetics

, 20:169 | Cite as

Identification of a novel mutation of NOG in family with proximal symphalangism and early genetic counseling

  • Cong Ma
  • Lv Liu
  • Fang-Na Wang
  • Hai-Shen Tian
  • Yan Luo
  • Rong Yu
  • Liang-Liang FanEmail author
  • Ya-Li LiEmail author
Open Access
Case report
Part of the following topical collections:
  1. Clinical-Molecular Genetics and Cytogenetics

Abstract

Background

Proximal symphalangism is a rare disease with multiple phenotypes including reduced proximal interphalangeal joint space, symphalangism of the 4th and/or 5th finger, as well as hearing loss. At present, at least two types of proximal symphalangism have been identified in the clinic. One is proximal symphalangism-1A (SYM1A), which is caused by genetic variants in Noggin (NOG), another is proximal symphalangism-1B (SYM1B), which is resulted from Growth Differentiation Factor 5 (GDF5) mutations.

Case presentation

Here, we reported a Chinese family with symphalangism of the 4th and/or 5th finger and moderate deafness. The proband was a 13-year-old girl with normal intelligence but symphalangism of the 4th finger in the left hand and moderate deafness. Hearing testing and inner ear CT scan suggested that the proband suffered from structural deafness. Family history investigation found that her father (II-3) and grandmother (I-2) also suffered from hearing loss and symphalangism. Target sequencing identified a novel heterozygous NOG mutation, c.690C > G/p.C230W, which was the genetic lesion of the affected family. Bioinformatics analysis and public databases filtering further confirmed the pathogenicity of the novel mutation. Furthermore, we assisted the family to deliver a baby girl who did not carry the mutation by genetic counseling and prenatal diagnosis using amniotic fluid DNA sequencing.

Conclusion

In this study, we identified a novel NOG mutation (c.690C > G/p.C230W) by target sequencing and helped the family to deliver a baby who did not carry the mutation. Our study expanded the spectrum of NOG mutations and contributed to genetic diagnosis and counseling of families with SYM1A.

Keywords

Proximal symphalangism Deafness NOG mutation Prenatal diagnosis 

Abbreviations

BMPs

Bone morphogenetic proteins

GDF5

Growth Differentiation Factor 5

kb

Kilobases

NOG

Noggin

SYM1A

proximal symphalangism-1A

SYM1B

proximal symphalangism-1B

Background

Proximal symphalangism is a rare genetic disorder of congenital limb malformation, characterized by ankylosis of the proximal interphalangeal joints, carpal and tarsal bone fusion, and, in some cases, conductive deafness and premature ovarian failure [1, 2]. The typical features of proximal symphalangism are reduced proximal interphalangeal joint space, symphalangism of the 4th and/or 5th finger [3, 4]. As early as in 1916, Cushing has described an American family with ankylosis of the proximal interphalangeal joints, and he named this heterozygote autosomal dominant disease as symphalangism [5].

At present, there are two types of diseases in the proximal symphalangism family: (1) Proximal symphalangism-1A (SYM1A, OMIM # 185800), which iss caused by genetic variants in Noggin (NOG) [6, 7]; (2) Proximal symphalangism-1B (SYM1B), which is resulted from Growth Differentiation Factor 5 (GDF5) mutations [8, 9]. In addition, some other diseases may be also related to proximal symphalangism, such as tarsal-carpal coalition syndrome, multiple synostoses syndrome, and brachydactyly, etc. [10, 11].

In this study, we employed target sequencing to explore the genetic lesion of a Chinese family with symphalangism of the 4th and/or 5th finger and moderate deafness. A novel mutation (c.690C > G/p.C230W) of NOG was identified in all affected individuals in this family. Furthermore, after genetic counseling and prenatal diagnosis with us, the mother successfully delivered a baby girl who did not carry the mutation.

Case presentation

A family from North of China (Hebei Province) with eight members across three generations participated in the study (Fig. 1a). The proband (III-2) was a 13-year-old girl with normal intelligence but symphalangism of the 4th finger in the left hand (Fig. 1b) and moderate deafness (Fig. 1c). Inner ear CT scan found abnormal inner ear structure (cochlear hypoplasia) and abnormal calcification (inner ear bone thickening and increased density) (Fig. 1d). Family history investigation found that her father (II-3) and grandmother (I-2) also suffered from hearing loss and symphalangism (Fig. 1a, e). Her grandmother has died six years ago. Her father showed the symphalangism of the 4th finger in left hand (Fig. 1e, f). He had performed the vestibulotomy and recovered the hearing one year ago. They went to the Department of Reproductive Genetics, HeBei General Hospital because the mother was pregnant with the second baby. They wanted to detect whether the second baby was normal or not.
Fig. 1

The Clinical data of the family. a The pedigree of this family. Black circles/squares are affected, white circles/squares are unaffected. N means Normal, M indicates Mutation. Arrow indicates the proband. b The proband showed the symphalangism of the 4th finger in the left hand. c Hearing testing suggests the proband suffering from moderate deafness. d Inner ear CT showed abnormal inner ear structure and abnormal calcification. The red circles marked the abnormal regions which indicated cochlear hypoplasia, inner ear bone thickening and increased density. e The symphalangism of the 4th finger in II-3. f Hands X-ray of III-2. The red circles marked the abnormal regions

Genetic analysis

We selected the proband’s genomic DNA to perform the target sequencing to detect the disease-causing mutations by Sinopath Diagnosis Company (Beijing, China). Target sequencing yielded 3.71 Gb of data with 99.088% coverage of the target region and 97.530% of the target covered over 10×. After filtering dbSNP132, 1000G, EXAC, and GenomAD database (MAF < 0.01), only 12 mutation were left. We then conducted the co-segregation analysis by Sanger sequencing and only seven variants were exist in affected individuals and were absent in healthy members (Table 1). We further performed the bioinformatics analysis including MutationTaster, SIFT, Polyphen-2, PANTHER, ToppGene function analysis, OMIM clinical phenotype analysis and ACMG classification (Table 1), we highly suspected the novel mutation (c.690C > G/p.C230W) of NOG, belonging to PM1 and PM2 in ACMG guidelines [12], was responsible for the family with SMY1A. This mutation resulted in a substitution of in polar amino acid cysteine by nonpolar amino acid tryptophan in the codon 230 of exon 1 of NOG gene, and was not presented in our 200 control cohorts. Noggin amino acid sequence alignment analysis suggested that this mutation was located in a highly evolutionarily conserved site (Fig. 2b). In addition, we also constructed a part model of the Noggin protein using SWISS-MODEL (https://swissmodel.expasy.org) (Fig. 2c) and, after applying SDM software (http://marid.bioc.cam.ac.uk/sdm2/prediction) to analyze the structure, it was found that this novel mutation might increase the solvent accessibility (WT:16.9% and Mutant: 39.9%) and reduce the stability of the Noggin protein.
Table 1

The mutations list after data filtering and co-segregation analysis

CHR

POS

RB

AB

Gene

Mutation

SIFT

PolyPhen-2

MutationTaster

PANTHER

OMIM clinical phenotype

ToppGene function

ACMG classification

1

45,481,060

C

T

UROD

NM_000374: c.994C > T, p.R332C

0,D

0.94,D

0.99,D

AD or AR: Porphyria cutanea tarda

heme biosynthetic process

BP5

2

149,216,410

G

A

MBD5

NM_018328: c.83G > A, p.R28H

0,D

0.99,D

0.99,D

P

AD: Mental retardation

response to growth hormone

BP5

2

189,953,479

G

T

COL5A2

NM_000393: c.587G > T, p.A196D

0.29,T

0.98,D

0.99,D

AD: Ehlers-Danlos syndrome

regulation of endodermal cell differentiation

BP4, BP5

3

38,674,642

G

A

SCN5A

NM_198056: 157G > A, p.R53W

0,D

0.36,B

0.95,D

P

AD: Atrial fibrillation

voltage-gated sodium channel activity

BP4, BP5

3

184,953,112

G

A

EHHADH

NM_001966: c.317G > A, p.A106V

0,D

0.99,D

0.99,D

P

AD: Fanconi renotubular syndrome

peroxisomal transport

BP5

17

48,701,856

G

A

CACNA1G

NM_018896: c.6365G > A, p.R2122H

0.04,D

0.01,B

0.8,D

P

AD: Spinocerebellar ataxia

voltage-gated calcium channel

BP4, BP5

17

54,672,274

C

G

NOG

NM_005450: c.690C > G, p.C230W

0,D

0.99,D

0.99,D

D

AD: Symphalangism proximal

fibroblast growth factor receptor signaling pathway

PM1, PM2

CHR Chromosome, POS position, RB reference sequence base, AB alternative base identified, D damaging, P probably damaging, B Benign, T Tolerated, AR autosomal recessive, AD autosomal dominant, BP Benign Supporting, PM Pathogenicity Moderate

Fig. 2

Genetic analysis of the family. a Sanger DNA sequencing chromatogram demonstrates the heterozygosity for a NOG mutation (c.690C > G/p.C230W). b Analysis of the mutation and protein domains of Noggin. The C230 affected amino acid locates in the highly conserved amino acid region in different mammals (from Ensembl). The black arrow and red words show the C230 site. c Swiss-model analyzed the Noggin structures of WT and Mutated (p.C230W). d The healthy hands of III-3 and normal sequences of amniotic fluid DNA

Prenatal diagnosis

When the parents came to our hospital, the mother has been pregnant with the second baby for 17 weeks and they wanted to have a healthy baby. According to ACMG classification, the novel mutation (c.690C > G/p.C230W) of NOG belongs to PM1 and PM2. Simultaneously, target sequencing only identified this mutation as a pathogenic variant. So, we highly believed the novel mutation (c.690C > G/p.C230W) of NOG was the genetic lesion of the family with proximal symphalangism and hearing loss. We then performed the Sanger sequencing of amniotic fluid DNA to detect the mutation, fortunately, the results showed a normal allele of the second baby. And 22 weeks later, the mother delivered a 3.4-kg healthy girl (Fig. 2d).

Discussion

The human NOG gene encoding Noggin protein is located on chromosome 17q22, and it consists of one exon, spanning approximately 1.9 kilobases (kb) [6]. Noggin protein is involved in the development of many body tissues, including nerve tissue, muscles, and bones and the role of Noggin in bone development makes it significant for proper joint formation [13]. According to previous researches, Noggin protein can interact with bone morphogenetic proteins (BMPs) and regulate the development of bone and other tissues [14]. In detail, the Noggin protein regulates the activity of BMPs by binding to them and blocking them from attaching to the downstream receptor, which results in a decrease in BMP signaling [15]. In our research, the novel mutation (c.690C > G/p.C230W) of NOG can increase the solvent accessibility and reduce the stability of the Noggin, which may active the BMP signal pathway and lead to bone diseases.

In 1999, five NOG mutations were identified in unrelated families with symphalangism (SYM1A) and a de novo mutation in a patient with unaffected parents [6]. Interestingly, a wide variety of bone development anomalies, including tarsal/carpal coalition syndrome [10], brachydactyly [16], multiple synostoses syndrome [17], Stapes ankylosis with broad thumbs and toes [18], have been reported in patients with NOG mutations. Similar observations were also reported in the families even with the same mutation [16, 19]. Therefore, the pleiotropic types of bone diseases and significant genetic heterogeneity make it difficult to be diagnosed. We summarized the previous reports and found that approximately 57 mutations (60 patients) of NOG have been identified in different types of disorders (Table 2).
Table 2

The summary of reported mutations of NOG

No.

Mutation

Phenotypes

Reference

1

p. Leu20fs

Multiple synostoses syndrome

Takahashi et al. (2001)

2

p. Pro35Ala

Brachydactyly type B

Lehmann et al. (2007)

3

p. Pro35Ser

Teunissen-Cremers syndrome

Hirshoren et al. (2008)

4

p. Pro35Ser

Proximal symphalangism

Mangino et al. (2002)

5

p. Pro35Ser

Brachydactyly type B

Lehmann et al. (2007)

6

p. Pro35Arg

Proximal symphalangism

Gong et al. (1999)

7

p. Pro35Arg

Tarsal–carpal coalition syndrome

Dixon et at. (2001)

8

p. Ala36Pro

Brachydactyly type B

Lehmann et al. (2007)

9

p. Pro37Arg

Tarsal–carpal coalition syndrome

Debeer et al. (2004)

10

p. Pro42Ala

Multiple synostoses syndrome

Debeer et al. (2005)

11

p. Pro42Ser

Proximal symphalangism

Sha et al. (2019)

12

p. Pro42Arg

Multiple synostoses syndrome

Oxley et al. (2008)

13

p. Pro42Thr

Multiple synostoses syndrome

Aydin, H et al. (2013)

14

p. Val44fs

Teunissen-Cremers syndrome

Weekamp et al. (2005)

15

p. Glu48Lys

Brachydactyly type B

Lehmann et al. (2007)

16

p. Glu48Lys

Proximal symphalangism

Kosaki et al. (2004)

17

p. Pro50Arg

Tarsal–carpal coalition syndrome

Debeer et al. (2005)

18

p. Asp55Tyr

Proximal symphalangism

Xiong et al. (2019)

19

p. Glu85fs

Stapes ankylosis with broad thumb and toes

Brown et al. (2002)

20

p. Arg87fs

Multiple synostoses syndrome

Lee et al. (2014)

21

p. Gly91Cys

Fibrodysplasia ossificans progressiva

Kaplan et al. (2008)

22

p. Gly92Arg

Fibrodysplasia ossificans progressiva

Kaplan et al. (2008)

23

p. Gly92Glu

Fibrodysplasia ossificans progressiva

Kaplan et al. (2008)

24

p. Ala95Thr

Fibrodysplasia ossificans progressiva

Kaplan et al. (2008)

25

p. Ala102fs

Proximal symphalangism

Thomeer et al. (2011)

26

p. Gln110X

Stapes ankylosis with broad thumb and toes

Brown et al. (2002)

27

p. Leu129X

Proximal symphalangism

Takahashi et al. (2001)

28

p.Gln131X

Stapes ankylosis with broad thumbs and toes

Takashi etal. (2014)

29

p. Lys133X

Stapes ankylosis with broad thumb and toes

Takano et al. (2016)

30

p. Arg136Cys

Proximal symphalangism

Masuda et al. (2014)

31

p. Trp150Cys

Proximal symphalangism

Pan et al. (2015)

32

p. Cys155Phe

Stapes ankylosis with symphalangism

Usami et al. (2012)

33

p. Cys155Ser

Proximal symphalangism

Usami et al. (2012)

34

p. Arg167Gly

Brachydactyly type B

Lehmann et al. (2007)

35

p. Arg167Cys

Proximal symphalangism

Liu et al. (2015)

36

p. Cys184Tyr

Proximal symphalangism

Takahashi et al. 2001

37

p. Cys184Phe

Proximal symphalangism

Usami et al. 2012

38

p. Pro187Ser

Brachydactyly type B

Lehmann et al. (2007)

39

p. Pro187Ala

Proximal symphalangism

Ganaha et al. (2015)

40

p. Glu188fs

Teunissen-Cremers syndrome

Weekamp et al. (2005)

41

p. Gly189Cys

Proximal symphalangism

Gong et al. (1999)

42

p. Met190Val

Multiple synostoses syndrome

Oxley et al. (2008)

43

p. Leu203Pro

Teunissen-Cremers syndrome

Weekamp et al. (2005)

44

p. Arg204Leu

Tarsal/carpal coalition syndrome

Dixon et al. (2001)

45

p. Arg204Gln

Tarsal-carpal coalition syndrome

Das et al. (2018)

46

p. Trp205X

Multiple synostoses syndrome

Dawson et al. (2006)

47

p. Trp205Cys

Facioaudiosymphalangism syndrome

van den Ende et al. (2005)

48

p. Trp205fs

Stapes ankylosis with broad thumb and toes

Emery et al. (2009)

49

p. Cys215X

Stapes ankylosis with broad thumb and toes

Usami et al. (2012)

50

p. Trp217Gly

Multiple synostoses syndrome

Gong et al. (1999)

51

p. Ile220Asn

Proximal symphalangism

Gong et al. (1999)

52

p. Ile220fs

Proximal symphalangism

Gong et al. (1999)

53

p. Tyr222Asp

Proximal symphalangism

Gong et al. (1999)

54

p. Tyr222Cys

Proximal symphalangism

Gong et al. (1999)

55

p. Tyr222Cys

Tarsal–carpal coalition syndrome

Dixon et al. (2001)

56

p. Pro223Leu

Proximal symphalangism

Gong et al. (1999)

57

p. Cys228Gly

Stapes ankylosis with broad thumb and toes

Ishino et al. (2015)

58

p. Cys228Ala

Multiple synostoses syndrome

Ganaha et al. (2015)

59

p. Cys230Tyr

Multiple synostoses syndrome

Bayat et al. (2016)

60

p. Cys230Trp

Proximal symphalangism

Present study

61

p. Cys232Trp

Multiple synostoses syndrome

Rudnik-Schöneborn et al. (2010)

Bold words indicate the patients with deafness

In this study, a family with symphalangism and moderate deafness was investigated by target sequencing. Genetic analysis found a novel mutation (c.690C > G/p.C230W) of NOG in two affected members. Of note, both of two patients with p.C230W in the family were associated with hearing loss. To date, 29 mutations have been reported in symphalangism patients related to deafness (Table 2) [11]. And the mutation p.C230W was the fifth report related to NOG mutation, although some Chinese journals have also published some reported mutations. Meanwhile, this difference also suggested that there were still a lot of novel mutations need to discovery in Chinese population.

The p.C230W mutation disrupts the cysteine knot motif of the C-terminal domain of Noggin (amino acids 155–232), which contains a series of nine cysteine residues and was shown to target the molecule to a specific receptor protein [20, 21]. The similar mutations (p.C228G, p.C228S, p.C230Y and p.C232W) have been identified in patients with symphalangism and hearing loss, which indicated that mutations in cysteine residues may be related to abnormal development of auditory ossicles and hearing loss [19, 22, 23, 24].

In clinical genetics, the aim of mutation detection is to make contributions to genetic diagnosis and counseling. In this study, we identified the genetic lesion of the family by target sequencing. All the filtered data were shown in Table 1. We not only performed the informatics analysis of the novel mutation by multi-different algorithm based bioinformatics programs, but also followed the ACMG guidelines to estimate the pathogenicity of the novel mutation strictly (PM1 and PM2). Finally, we highly believed that the novel mutation (p.C230W) of NOG may be the genetic lesion of the family. We then assisted the family to get a healthy baby by amniotic fluid DNA sequencing referring to other people’s research [25]. Prenatal diagnosis not only helped the patient to delivery healthy baby and improved the population quality but also relieved psychological and financial stress [26]. Our study provided a successful example for genetic counseling and prenatal diagnosis of patients with SYM1A.

Conclusions

We reported a novel NOG mutation (c.690C > G/p.C230W) in a three-generation family with SYM1A. And we helped them delivery a girl baby who did not carry the mutation by genetic counseling and prenatal diagnosis. Our study not only presented the important role of NOG in proximal symphalangism and deafness but also expanded the spectrum of NOG mutations and contributed to genetic diagnosis and counseling of families with SYM1A.

Notes

Acknowledgements

We thank all subjects for participating in this study.

Authors’ contributions

C M and L L carried out the sample collecting and genetic testing, F-N W, H-S T and Y L collected the clinical data, R Y performed the bioinformatics analysis, Y-L L and L-L F designed the project and wrote the manuscript, and L-L F revised the manuscript. All authors read and approved the final manuscript.

Funding

During the whole course of this study, the study design, data collection, data analysis, data interpretation and manuscript preparation were mainly supported by National Natural Science Foundation of China (81800220) and Hunan province Natural Science Foundation (2019JJ50890). Part of the data analysis, which is the prenatal diagnosis was supported by Hebei Science and Technology Plan Project (17277728D).

Ethics approval and consent to participate

Written informed consent was obtained from each individual and the investigation was approved by the Institutional Review Board of HeBei General Hospital.

Consent for publication

Written consent was obtained from all the participants or their guardians for the publication of this study.

Competing interests

The authors declare that they have no competing interests.

References

  1. 1.
    Plett SK, Berdon WE, Cowles RA, Oklu R, Campbell JB. Cushing proximal symphalangism and the NOG and GDF5 genes. Pediatr Radiol. 2008;38(2):209–15.CrossRefGoogle Scholar
  2. 2.
    Kadi N, Tahiri L, Maziane M, Mernissi FZ, Harzy T. Proximal symphalangism and premature ovarian failure. Joint Bone Spine. 2012;79(1):83–4.CrossRefGoogle Scholar
  3. 3.
    Pasha AS, Weimer M. Symphalangism. Arthritis Rheumatol. 2016;68(9):2327.CrossRefGoogle Scholar
  4. 4.
    Cushing H. Hereditary anchylosis of the proximal phalangeal joints (symphalangism). Clin Orthop Relat Res. 1915;2002(401):4–5 discussion 4.Google Scholar
  5. 5.
    Cushing H. Hereditary Anchylosis of the proximal Phalan-Geal joints (Symphalangism). Genetics. 1916;1(1):90–106.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Gong Y, Krakow D, Marcelino J, Wilkin D, Chitayat D, Babul-Hirji R, Hudgins L, Cremers CW, Cremers FP, Brunner HG, et al. Heterozygous mutations in the gene encoding noggin affect human joint morphogenesis. Nat Genet. 1999;21(3):302–4.CrossRefGoogle Scholar
  7. 7.
    Sha Y, Ma D, Zhang N, Wei X, Liu W, Wang X. Novel NOG (p.P42S) mutation causes proximal symphalangism in a four-generation Chinese family. BMC Med Genet. 2019;20(1):133.CrossRefGoogle Scholar
  8. 8.
    Leonidou A, Irving M, Holden S, Katchburian M. Recurrent missense mutation of GDF5 (p.R438L) causes proximal symphalangism in a British family. World J Orthop. 2016;7(12):839–42.CrossRefGoogle Scholar
  9. 9.
    Seemann P, Schwappacher R, Kjaer KW, Krakow D, Lehmann K, Dawson K, Stricker S, Pohl J, Ploger F, Staub E, et al. Activating and deactivating mutations in the receptor interaction site of GDF5 cause symphalangism or brachydactyly type A2. J Clin Invest. 2005;115(9):2373–81.CrossRefGoogle Scholar
  10. 10.
    Das Bhowmik A, Salem Ramakumaran V, Dalal A. Tarsal-carpal coalition syndrome: report of a novel missense mutation in NOG gene and phenotypic delineation. Am J Med Genet A. 2018;176(1):219–24.CrossRefGoogle Scholar
  11. 11.
    Takano K, Ogasawara N, Matsunaga T, Mutai H, Sakurai A, Ishikawa A, Himi T. A novel nonsense mutation in the NOG gene causes familial NOG-related symphalangism spectrum disorder. Hum Genome Var. 2016;3:16023.CrossRefGoogle Scholar
  12. 12.
    Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405–24.CrossRefGoogle Scholar
  13. 13.
    Marcelino J, Sciortino CM, Romero MF, Ulatowski LM, Ballock RT, Economides AN, Eimon PM, Harland RM, Warman ML. Human disease-causing NOG missense mutations: effects on noggin secretion, dimer formation, and bone morphogenetic protein binding. Proc Natl Acad Sci U S A. 2001;98(20):11353–8.CrossRefGoogle Scholar
  14. 14.
    Schmidt-Bleek K, Willie BM, Schwabe P, Seemann P, Duda GN. BMPs in bone regeneration: less is more effective, a paradigm-shift. Cytokine Growth Factor Rev. 2016;27:141–8.CrossRefGoogle Scholar
  15. 15.
    Wan DC, Pomerantz JH, Brunet LJ, Kim JB, Chou YF, Wu BM, Harland R, Blau HM, Longaker MT. Noggin suppression enhances in vitro osteogenesis and accelerates in vivo bone formation. J Biol Chem. 2007;282(36):26450–9.CrossRefGoogle Scholar
  16. 16.
    Lehmann K, Seemann P, Silan F, Goecke TO, Irgang S, Kjaer KW, Kjaergaard S, Mahoney MJ, Morlot S, Reissner C, et al. A new subtype of brachydactyly type B caused by point mutations in the bone morphogenetic protein antagonist NOGGIN. Am J Hum Genet. 2007;81(2):388–96.CrossRefGoogle Scholar
  17. 17.
    Lee BH, Kim OH, Yoon HK, Kim JM, Park K, Yoo HW. Variable phenotypes of multiple synostosis syndrome in patients with novel NOG mutations. Joint Bone Spine. 2014;81(6):533–6.CrossRefGoogle Scholar
  18. 18.
    Thomeer HG, Admiraal RJ, Hoefsloot L, Kunst HP, Cremers CW. Proximal symphalangism, hyperopia, conductive hearing impairment, and the NOG gene: 2 new mutations. Otology Neurotol. 2011;32(4):632–8.CrossRefGoogle Scholar
  19. 19.
    Ganaha A, Kaname T, Akazawa Y, Higa T, Shinjou A, Naritomi K, Suzuki M. Identification of two novel mutations in the NOG gene associated with congenital stapes ankylosis and symphalangism. J Hum Genet. 2015;60(1):27–34.CrossRefGoogle Scholar
  20. 20.
    Groppe J, Greenwald J, Wiater E, Rodriguez-Leon J, Economides AN, Kwiatkowski W, Affolter M, Vale WW, Izpisua Belmonte JC, Choe S. Structural basis of BMP signalling inhibition by the cystine knot protein noggin. Nature. 2002;420(6916):636–42.CrossRefGoogle Scholar
  21. 21.
    Brown DJ, Kim TB, Petty EM, Downs CA, Martin DM, Strouse PJ, Moroi SE, Milunsky JM, Lesperance MM. Autosomal dominant stapes ankylosis with broad thumbs and toes, hyperopia, and skeletal anomalies is caused by heterozygous nonsense and frameshift mutations in NOG, the gene encoding noggin. Am J Hum Genet. 2002;71(3):618–24.CrossRefGoogle Scholar
  22. 22.
    Rudnik-Schoneborn S, Takahashi T, Busse S, Schmidt T, Senderek J, Eggermann T, Zerres K. Facioaudiosymphalangism syndrome and growth acceleration associated with a heterozygous NOG mutation. Am J Med Genet A. 2010;152A(6):1540–4.PubMedGoogle Scholar
  23. 23.
    Ishino T, Takeno S, Hirakawa K. Novel NOG mutation in Japanese patients with stapes ankylosis with broad thumbs and toes. Eur J Med Genet. 2015;58(9):427–32.CrossRefGoogle Scholar
  24. 24.
    Bayat A, Fijalkowski I, Andersen T, Abdulmunem SA, van den Ende J, Van Hul W. Further delineation of facioaudiosymphalangism syndrome: description of a family with a novel NOG mutation and without hearing loss. Am J Med Genet A. 2016;170(6):1479–84.CrossRefGoogle Scholar
  25. 25.
    Abou Tayoun AN, Spinner NB, Rehm HL, Green RC, Bianchi DW. Prenatal DNA sequencing: clinical, counseling, and diagnostic laboratory considerations. Prenat Diagn. 2018;38(1):26–32.CrossRefGoogle Scholar
  26. 26.
    Vermeesch JR, Voet T, Devriendt K. Prenatal and pre-implantation genetic diagnosis. Nat Rev Genet. 2016;17(10):643–56.CrossRefGoogle Scholar

Copyright information

© The Author(s). 2019

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors and Affiliations

  1. 1.Departments of Reproductive GeneticsHeBei General HospitalShiJiaZhuangChina
  2. 2.Department of Respiratory Medicine, Diagnosis and Treatment Center of Respiratory Disease, Diagnosis and Treatment Center of Respiratory Diseasethe Second Xiangya Hospital of Central South UniversityChangshaChina
  3. 3.Departments of Anesthesiology, the Second Xiangya HospitalCentral South UniversityChangshaChina
  4. 4.Department of Cell Biology, The School of Life SciencesCentral South UniversityChangshaChina

Personalised recommendations